Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-03-01 Replacement therapy
| Fludrocortisone |
|
Formulary
|
Tablets 100micrograms Fludrocortisone has very high mineralocorticoid activity and insignificant glucocorticoid activity. A combination of hydrocortisone and fludrocortisone are needed in primary adrenal deficiency states. |
 MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration |
|
Links
- AddisonsDisease.org
- BSPED: Adrenal Insufficiency Consensus Guidelines
- Diabetes UK: Diabetes when you’re unwell
LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
LSCMMG: GLP-1 patient contract- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Diabetes and driving
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NHSE: National Patient Safety Alert – Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period